DRMAW
Income statement / Annual
Last year (2023), Dermata Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Dermata Therapeutics, Inc.'s net income was -$7.79 M.
See Dermata Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$322.00 |
$1,355.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
-$322.00 |
-$1,355.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$4.07 M
|
$5.65 M
|
$3.46 M
|
$1.61 M
|
$2.62 M
|
| General & Administrative
Expenses |
$3.97 B
|
$4.02 M
|
$4.40 M
|
$1.57 M
|
$1.85 M
|
| Selling & Marketing
Expenses |
-$3.97 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$3.97 M
|
$4.02 M
|
$4.40 M
|
$1.57 M
|
$1.85 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$8.04 M |
$9.67 M |
$7.86 M |
$3.17 M |
$4.47 M |
| Cost And Expenses |
$8.04 M |
$9.67 M |
$7.86 M |
$3.17 M |
$4.47 M |
| Interest Income |
$247,216.00 |
$63,573.00 |
$45.61 |
$197.27 |
$250.75 |
| Interest Expense |
$0.00 |
$0.00 |
$45,613.00 |
$197,269.00 |
$250,748.00 |
| Depreciation &
Amortization |
$8.04 M
|
$9.67 M
|
$322.00
|
$322.00
|
$1,355.00
|
| EBITDA |
$247,216.00
|
$0.00
|
-$7.86 M
|
-$3.17 M
|
-$4.47 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$247,216.00
|
$63,573.00
|
-$45,613.00
|
-$63,677.00
|
-$250,748.00
|
| Income Before Tax |
-$7.79 M |
-$9.61 M |
-$7.90 M |
-$3.24 M |
-$4.72 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$9,674.49 |
$45,613.00 |
$197,269.00 |
$250,748.00 |
| Net Income |
-$7.79 M |
-$9.61 M |
-$7.95 M |
-$3.43 M |
-$4.97 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
| EPS |
-40.18 |
-13.92 |
-15.27 |
-6.6 |
-9.55 |
| EPS Diluted |
-39.98 |
-13.92 |
-15.27 |
-6.6 |
-9.55 |
| Weighted Average Shares
Out |
$194,000.00
|
$690,666.00
|
$520,539.00
|
$520,539.00
|
$520,539.00
|
| Weighted Average Shares
Out Diluted |
$194,960.00
|
$690,666.00
|
$520,539.00
|
$520,539.00
|
$520,539.00
|
| Link |
|
|
|
|
|
